Familial uveal melanoma and other tumours in 25 families with monoallelic germline MBD4 variants.


Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
07 Dec 2023
Historique:
received: 17 07 2023
revised: 02 11 2023
accepted: 18 11 2023
medline: 7 12 2023
pubmed: 7 12 2023
entrez: 7 12 2023
Statut: aheadofprint

Résumé

Monoallelic germline MBD4 pathogenic variants (PVs) were recently reported to cause a predisposition to uveal melanoma (UM), associated with a specific tumour mutational signature and good response to immunotherapy. Monoallelic tumour PVs have also been described in brain tumours, breast cancers and myxofibrosarcomas, whereas biallelic germline MBD4 PVs have been involved in a recessive hereditary adenomatous polyposis and a specific type of acute myeloid leukaemia. We analysed MBD4 for all patients diagnosed with UM at Institut Curie since July 2021 and in the 3,240 consecutive female probands explored at the Institut Curie for suspicion of predisposition to breast cancer between July 2021 and February 2023. We here describe 25 families whose probands carry a monoallelic germline PV in MBD4. Eighteen of them presented with UM (including a case of multiple UM), and 7 with breast cancer. Family histories showed the first familial case of UM in monoallelic MBD4 PV carriers and other various types of cancers in relatives, especially breast, renal and colorectal tumours. Monoallelic MBD4 PV may thus explain some familial and multiple UM, as well as various cancer types, expanding the tumour spectrum of this predisposition. Further genetic testing in relatives combined with molecular tumour analyses will help define the tumour spectrum and estimate each tumour risk.

Sections du résumé

BACKGROUND BACKGROUND
Monoallelic germline MBD4 pathogenic variants (PVs) were recently reported to cause a predisposition to uveal melanoma (UM), associated with a specific tumour mutational signature and good response to immunotherapy. Monoallelic tumour PVs have also been described in brain tumours, breast cancers and myxofibrosarcomas, whereas biallelic germline MBD4 PVs have been involved in a recessive hereditary adenomatous polyposis and a specific type of acute myeloid leukaemia.
METHODS METHODS
We analysed MBD4 for all patients diagnosed with UM at Institut Curie since July 2021 and in the 3,240 consecutive female probands explored at the Institut Curie for suspicion of predisposition to breast cancer between July 2021 and February 2023.
RESULTS RESULTS
We here describe 25 families whose probands carry a monoallelic germline PV in MBD4. Eighteen of them presented with UM (including a case of multiple UM), and 7 with breast cancer. Family histories showed the first familial case of UM in monoallelic MBD4 PV carriers and other various types of cancers in relatives, especially breast, renal and colorectal tumours.
CONCLUSIONS CONCLUSIONS
Monoallelic MBD4 PV may thus explain some familial and multiple UM, as well as various cancer types, expanding the tumour spectrum of this predisposition. Further genetic testing in relatives combined with molecular tumour analyses will help define the tumour spectrum and estimate each tumour risk.

Identifiants

pubmed: 38060262
pii: 7461189
doi: 10.1093/jnci/djad248
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Marie-Charlotte Villy (MC)

Department of Genetics, Institut Curie, Paris, France.
Université Paris Cité, Paris, France.

Anaïs Le Ven (A)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Paris, France.

Marine Le Mentec (M)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Julien Masliah-Planchon (J)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Alexandre Houy (A)

Paris Sciences & Lettres Research University, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Paris, France.

Ivan Bièche (I)

Department of Genetics, Institut Curie, Paris, France.
Université Paris Cité, Paris, France.

Sophie Vacher (S)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Anne Vincent-Salomon (A)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Catherine Dubois d'Enghien (CD)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Mathias Schwartz (M)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Sophie Piperno-Neumann (S)

Paris Sciences & Lettres Research University, Paris, France.
Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.

Alexandre Matet (A)

Université Paris Cité, Paris, France.
Department of Ocular Oncology, Institut Curie, Paris, France.

Denis Malaise (D)

Paris Sciences & Lettres Research University, Paris, France.
Department of Ocular Oncology, Institut Curie, Paris, France.

Virginie Bubien (V)

Department of Genetics, Institut Bergonié, Bordeaux, France.

Alain Lortholary (A)

Medical Oncology, GINECO-Hôpital Privé du Confluent, Nantes, France.

Amal Ait Omar (A)

Department of Gastroenterology, AP-HP, Hôpital Avicenne, Bobigny, France.

Mathias Cavaillé (M)

Department of Oncogenetics, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, AURAGEN, Clermont-Ferrand, F-63011 F-63000, France.

Dominique Stoppa-Lyonnet (D)

Department of Genetics, Institut Curie, Paris, France.
Université Paris Cité, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Paris, France.

Nathalie Cassoux (N)

Université Paris Cité, Paris, France.
Department of Ocular Oncology, Institut Curie, Paris, France.

Marc-Henri Stern (MH)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Paris, France.

Manuel Rodrigues (M)

Paris Sciences & Lettres Research University, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Paris, France.
Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.

Lisa Golmard (L)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.

Chrystelle Colas (C)

Department of Genetics, Institut Curie, Paris, France.
Paris Sciences & Lettres Research University, Paris, France.
Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Paris, France.

Classifications MeSH